Priser
Platform
Blog
Om os
Download
300110
Huaren Pharmaceutical Co
Shenzhen Stock Exchange
0

Om

Huaren Pharmaceutical Co., Ltd. is a diversified entity in the pharmaceutical industry dedicated to the research, development, production, and distribution of a wide array of medical products. The company focuses on creating medications that address chronic conditions and essential health needs, thereby significantly impacting the healthcare sector. Huaren's portfolio includes prescription drugs, over-the-counter medications, and health supplements aimed at improving patient outcomes and wellbeing. As a key player in the pharmaceutical supply chain, the company contributes to both local and international markets, influencing public health policies and accessibility to medical treatments. Given the increasing demand for innovative health solutions, Huaren Pharmaceutical Co., Ltd. plays a crucial role in the ongoing advancements within the global medical landscape, emphasizing quality and reliability in its product offerings.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I HUAREN PHARMACEUTICAL CO MED ENDAVU: Køb Huaren Pharmaceutical Co ($300110) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Huaren Pharmaceutical Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

Ticker300110
Land
Kina
Antal medarbejdere2.491
Hjemmesideqdhuaren.com
SektorSundhed
IndustriLægemiddelproducenter - Specialitet og generisk

Udbytter

0,03CNH
'19
0,01CNH
'20
0,02CNH
'21
0,02CNH
'22
0,02CNH
'23
0,02CNH
'24
Ex-udbytte-dato10. jul. 2024
Udbytteafkast0,68%